182 related articles for article (PubMed ID: 35738585)
1. Tumor Budding as a Predictive Marker of Relapse and Survival in Patients With Stage II Colon Cancer.
Saito K; Okuyama T; Miyazaki S; Oi H; Mitsui T; Noro T; Takeshita E; Ono Y; Urahashi T; Tajima H; Yoshitomi H
In Vivo; 2022; 36(4):1820-1828. PubMed ID: 35738585
[TBL] [Abstract][Full Text] [Related]
2. Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer.
Lee VWK; Chan KF
Pathol Res Pract; 2018 Mar; 214(3):402-407. PubMed ID: 29487008
[TBL] [Abstract][Full Text] [Related]
3. Is there no need to discuss adjuvant chemotherapy in stage II colon cancer patients with high tumor budding and lymphovascular invasion?
Zenger S; Gurbuz B; Can U; Erginoz E; Ozata IH; Yilmaz SP; Taskin OC; Peker O; Adsay V; Balik E; Bugra D
Langenbecks Arch Surg; 2023 Mar; 408(1):127. PubMed ID: 36973561
[TBL] [Abstract][Full Text] [Related]
4. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsuda C; Nakamoto Y; Kotake M; Kurachi K; Egawa T; Yasumasa K; Murata K; Ikawa O; Shinji S; Murotani K; Matsui S; Teramukai S; Tomita N; Sugihara K;
J Clin Oncol; 2019 Aug; 37(22):1886-1894. PubMed ID: 31180819
[TBL] [Abstract][Full Text] [Related]
5. Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer.
Okuyama T; Sameshima S; Takeshita E; Mitsui T; Noro T; Ono Y; Noie T; Ban S; Oya M
BMC Cancer; 2020 Sep; 20(1):842. PubMed ID: 32883261
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening program.
Pihlmann Kristensen M; Korsgaard U; Timm S; Hansen TF; Zlobec I; Hager H; Kjær-Frifeldt S
Hum Pathol; 2024 Apr; 146():15-22. PubMed ID: 38428823
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
8. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
[TBL] [Abstract][Full Text] [Related]
9. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive values of tumour budding in stage IV colorectal cancer.
Nagata K; Shinto E; Yamadera M; Shiraishi T; Kajiwara Y; Okamoto K; Mochizuki S; Hase K; Kishi Y; Ueno H
BJS Open; 2020 Aug; 4(4):693-703. PubMed ID: 32472647
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological risk factors of Stage II colon cancer: results of a prospective study.
Santos C; López-Doriga A; Navarro M; Mateo J; Biondo S; Martínez Villacampa M; Soler G; Sanjuan X; Paules MJ; Laquente B; Guinó E; Kreisler E; Frago R; Germà JR; Moreno V; Salazar R
Colorectal Dis; 2013 Apr; 15(4):414-22. PubMed ID: 22974322
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam.
Dao TV; Nguyen CV; Nguyen QT; Vu HTN; Phung HT; Bui OT; Nguyen DK; Luong BV; Tran TV
Cancer Control; 2020; 27(1):1073274820968883. PubMed ID: 33136444
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
14. Association Between Obesity and Histological Tumor Budding in Patients With Nonmetastatic Colon Cancer.
Gan T; Schaberg KB; He D; Mansour A; Kapoor H; Wang C; Evers BM; Bocklage TJ
JAMA Netw Open; 2021 Apr; 4(4):e213897. PubMed ID: 33792733
[TBL] [Abstract][Full Text] [Related]
15. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M;
Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156
[TBL] [Abstract][Full Text] [Related]
16. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.
Park JS; Chon HJ; Jeung HC; Shin SJ; Rha SY; Ahn JB; Lee KY; Kim NK; Chung HC
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2051-9. PubMed ID: 27447697
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of tumor budding detection in stage II colon cancer].
Liu SJ; Yang XH; Ren JQ; Zhu XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):730-4. PubMed ID: 23980042
[TBL] [Abstract][Full Text] [Related]
18. The role of apical lymph node metastasis in right colon cancer.
Wang LM; Hirano YM; Ishii TM; Kondo HK; Hara KK; Obara N; Asari MH; Yamaguchi SK
Int J Colorectal Dis; 2020 Oct; 35(10):1887-1894. PubMed ID: 32514722
[TBL] [Abstract][Full Text] [Related]
19. Number of negative lymph nodes with a positive impact on survival of stage III colon cancer; a retrospective observation study for right side and left side colon.
Kuo YH; You JF; Hung HY; Chin CC; Chiang JM; Chang CH
BMC Cancer; 2022 Jan; 22(1):126. PubMed ID: 35100975
[TBL] [Abstract][Full Text] [Related]
20. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
